Home » Stocks » FULC

Fulcrum Therapeutics, Inc. (FULC)

Stock Price: $9.86 USD -0.07 (-0.70%)
Updated Oct 30, 2020 4:00 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 270.68M
Revenue (ttm) 2.75M
Net Income (ttm) -67.60M
Shares Out 27.45M
EPS (ttm) -14.92
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Oct 30, 2020
Last Price $9.86
Previous Close $9.93
Change ($) -0.07
Change (%) -0.70%
Day's Open 9.85
Day's Range 9.46 - 9.97
Day's Volume 111,196
52-Week Range 5.72 - 22.96

More Stats

Market Cap 270.68M
Enterprise Value 137.85M
Earnings Date (est) Nov 12, 2020
Ex-Dividend Date n/a
Shares Outstanding 27.45M
Float 13.60M
EPS (basic) -0.24
EPS (diluted) -14.92
FCF / Share -2.01
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 1.15M
Short Ratio 4.70
Short % of Float 8.43%
Beta n/a
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 98.43
PB Ratio 2.20
Revenue 2.75M
Operating Income -68.22M
Net Income -67.60M
Free Cash Flow -47.94M
Net Cash 132.83M
Net Cash / Share 4.84
Gross Margin 100.00%
Operating Margin -2,480.58%
Profit Margin -2,458.10%
FCF Margin -1,743.13%
ROA -40.60%
ROE -76.09%
ROIC -235.50%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Forecasts

Analyst Ratings (6)

Buy 4
Overweight 0
Hold 1
Underweight 1
Sell 0

Analyst Consensus: Buy

Price Target

$18.50*
(87.63% upside)
Low
11.0
Current: $9.86
High
25.0
Target: 18.50
*Average 12-month price target from 6 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year201920182017
Revenue---
Operating Income-84.22-33.50-22.99
Net Income-82.68-32.59-22.96
Shares Outstanding11.051.260.71
Earnings Per Share-8.13-31.14-35.68
Operating Cash Flow-39.48-22.56-20.07
Capital Expenditures-0.85-8.98-1.91
Free Cash Flow-40.34-31.54-21.98
Cash & Equivalents97.8173.890.41
Net Cash / Debt97.8173.890.41
Assets11085.774.34
Liabilities23.299.773.02
Book Value87.15-63.67-33.27
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Fulcrum Therapeutics, Inc.
Country United States
Employees 73
CEO Robert J. Gould

Stock Information

Ticker Symbol FULC
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: FULC
IPO Date July 18, 2019

Description

Fulcrum Therapeutics, a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule that is in Phase 2b clinical trial for the treatment of facioscapulohumeral muscular dystrophy, a rare, progressive, and disabling muscle wasting disorder that leads to significant physical impairments and disability; and FTX-6058, a small molecule designed to upregulate fetal hemoglobin in patients with sickle cell disease and ß-thalassemia. The company is also discovering drug targets for the treatments of duchenne muscular dystrophy, friedreich ataxia, myotonic dystrophy 1, and a-synucleinopathies, as well as neurological and pulmonary diseases. Fulcrum Therapeutics, Inc. has research and discovery collaboration agreement with Acceleron Pharma Inc. to identify biological targets to modulate specific pathways associated with a targeted indication within the pulmonary disease space; and has a strategic collaboration and license agreement with MyoKardia, Inc. to discover, develop, and commercialize novel targeted therapies for the treatment of genetic cardiomyopathies. Fulcrum Therapeutics, Inc. was founded in 2015 and is headquartered in Cambridge, Massachusetts.